Beranda › Kanker Laring › Ohio
Uji klinis Kanker Laring di Ohio
11 studi untuk Kanker Laring mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Miami Valley Hospital South, Centerville
- Miami Valley Hospital, Dayton
- Miami Valley Hospital North, Dayton
- dan 3 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- ProMedica Flower Hospital, Sylvania
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Miami Valley Hospital South, Centerville
- Premier Blood and Cancer Center, Dayton
- Miami Valley Hospital North, Dayton
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05136196Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06980038Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT05172245Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- Indu and Raj Soin Medical Center, Beavercreek
- Saint Elizabeth Boardman Hospital, Boardman
- dan 22 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Summa Health System - Akron Campus, Akron
- Aultman Health Foundation, Canton
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- dan 2 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- ProMedica Flower Hospital, Sylvania
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 19 hingga 110 · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT02012699Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- Ohio State University Medical Center, Columbus
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT01473784SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 28 Okt 2025 · NCT03452774Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.